Anthony Fauci, a key member of the White House coronavirus task force, said results from a clinical trial of a potential COVID-19 treatment showed “quite good news.”
Data from an international study of remdesivir showed patients treated with the drug recovered 31 percent faster than patients given a placebo, Fauci told reporters at the White House on Wednesday, alongside President Trump and Vice President Pence.
“Although a 31 percent improvement doesn’t seem like a knockout 100 percent, it is a very important proof of concept,” Fauci said. “What it has proven is that a drug can block this virus.”
He added the drug will be “the standard of care.”
Remdesivir patients also saw an 8 percent mortality rate, which is slightly lower, but not statistically significant, from the 11.6 percent mortality rate of placebo patients, Fauci said. The drug’s impact on the COVID-19 mortality rate needs further analysis, he said.
The clinical trial, which began in February, evaluated the safety and efficacy of remdesivir, an experimental drug developed by Gilead Sciences, in 1,063 hospitalized adults with COVID-19. The trial was the first in the U.S. to evaluate an experimental treatment for COVID-19…
To read the entire article from The Hill, click https://thehill.com/policy/healthcare/495262-fauci-touts-clinical-trial-of-covid-drug-as-quite-good-news
